NIPPON CHEMIPHAR CO.,LTD. (4539)

Price history

¥1,530Latest-25.0%

Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis

Business overview

The Company provides comprehensive healthcare services centered on pharmaceuticals. Its business is built around generic drugs, clinical diagnostic reagents (DropScreen), and new drug development. It operates primarily in China and Vietnam through its domestic and overseas bases, with plans to expand into the Middle East and Africa in the future. Its affiliated companies include 日本薬品工業, 日本薬品工業’s affiliated companies, ジャパンソファルシム, 化合物安全性研究所, and シャプロ. Overseas, it sells 8 products in 4 countries, promotes the adoption of clinical diagnostic reagents, and responds to fluctuations in authorized generic drug prices. As of March 2026, its overseas operations are centered in China and Vietnam. Looking ahead, it is pursuing expanded local production and sales, as well as pipeline expansion through alliances.

Recurring subjects

No threads yetThis company's filings have not been read yet. We are adding them progressively.

Companies sharing a theme

Documents

See all timely disclosures See all statutory filings

News

See all news

Key numbersShowing 8 of 19

PER

33.9How many years of earnings it would take to buy the stock. The market average is generally considered to be around 15.

PBR

0.34How many times the company's net assets? Around 1x is generally considered a benchmark.

ROE

-0.5%Earning power. A figure above 10% is generally considered good.

Dividend yield

0.0%The annual dividend as a percentage of the share price.

Market capitalization

¥6.6bnShare price × number of shares. The value of the entire company.

Equity ratio

37.3%The proportion of assets funded by money that does not have to be repaid.

Operating margin

-3.2%The percentage of revenue remaining from the company’s core business.

Revenue growth (3 years)

2.8%The average annual growth in sales over the past three years.

What to watch next

Shipments from the new equipment on the second floor of Building 3 at the Tsukuba plant will begin sequentially from May 2026, making the increase in production capacity visible

From May 2026 onward, sequentiallyImpact HighLikelihood Medium

Continued growth in the number of installed DropScreen clinical diagnostic reagent units, with the cumulative total exceeding 1,800, and progress in expanding distribution channels

At the next disclosure, quarterly or annualImpact MediumLikelihood High

Expected completion of patient enrollment for the oncology pipeline product DFP-17729, anticipated in May 2026, and updates on clinical progress

May 2026Impact MediumLikelihood Medium

Quantitative updates on the progress of the Phase III trial of DFP-14323 for EGFR mutation-positive non-small cell lung cancer, including the number of enrolled patients

Sequentially from 2026 onwardImpact MediumLikelihood Low

Updates on patient enrollment following the start of patient enrollment for NC-2800, a δ-opioid receptor agonist, in its Phase IIa trial in January 2026

From January 2026 onward, at the next updateImpact MediumLikelihood Low

What to watch next

Who owns itTop holders total 50.0%

Listed holders 50.0%Everyone else 50.0%

ジャパンソファルシム株式会社11.88%

公益財団法人山口記念科学振興財団8.22%

豊島薬品株式会社6.63%

Nippon Life Insurance Company3.94%

今村均3.45%

日本ケミファ従業員持株会3.35%

ZERIA PHARMACEUTICAL CO.,LTD.3.32%

上田八木短資株式会社3.25%

2 other listed holders5.91%

Who owns it
Holder	Ownership (%)
ジャパンソファルシム株式会社	11.88
公益財団法人山口記念科学振興財団	8.22
豊島薬品株式会社	6.63
Nippon Life Insurance Company	3.94
今村均	3.45
日本ケミファ従業員持株会	3.35
ZERIA PHARMACEUTICAL CO.,LTD.	3.32
上田八木短資株式会社	3.25
2 other listed holders	5.91

This company's documents

Filings

Timely disclosures